Neoadjuvant‐modified FOLFIRINOX vs nab‐paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection by Adam R. Wolfe, Dhivya Prabhakar, Vedat O. Yildiz, Jordan M. Cloyd, Mary Dillhoff, Laith Abushahin, Dayssy Alexandra Diaz, Eric D. Miller, Wei Chen, Wendy L. Frankel, Anne Noonan, Terence M. Williams

Get full text